Ozempic tops new Medicare price negotiation list

As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare Conference in San Francisco, the outgoing Biden administration at HHS dropped their farewell gift to the industry - the list of the next 15 drugs to be subject to what the government calls price negotiation and the industry calls price setting under the Inflation Reduction Act.

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together as a single drug